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Abstract
Background: Osteosarcoma is the most common primary bone malignancy with high local aggressiveness and
rapid metastasizing potential, resulting in poor survival. Increasing reports suggest that deregulated microRNAs
(miRNAs) might provide novel therapeutic targets for cancers. However, the expression of miR-26a and miR-27a in
osteosarcoma need further investigation in clinical samples. In our study, we evaluate the expression of these
miRNAs in osteosarcoma tissues and compared with paired adjacent non-tumor bone tissues using RT-qPCR.
Methods: Total RNA was purified from patients with osteosarcoma and noncancerous bone tissues. Real-time PCR
was applied to quantify the expression level of miR-26a and miR-27a. Moreover, the correlation of these markers
with clinicopathological characteristics was also evaluated in osteosarcoma patients. A cox proportional hazards
model was performed to assess multivariate analyses of prognostic values.
Results: Our result suggested that miR-26aexpression level in osteosarcoma bone tissue was significantly lower
than that in the paired noncancerous bone tissues. MiR-27a expression was higher in osteosarcoma bone tissue in
comparison with paired noncancerous bone tissues. The results indicated that low expression level of miR-26a and
high expression of miR-27a were associated with high TNM stage (P = 0.001; P = 0.012), tumor grade (P = 0.007;
P = 0.016), and distant metastasis (P = 0.004; P = 0.001). Kaplan-Meier analysis and log-rank test indicated that
patients with low expression of miR-26a and high expression of miR-27a had shorter overall survival (log-rank test:
P < 0.001). Multivariate Cox proportional hazards model analysis showed that low expression of miR-26a and high
expression of miR-27a (P = 0.021; P = 0.011), high TNM stage (P = 0.001; P = 0.003), tumor grade (P = 0.005; P = 0.01),
and distant metastasis.(P = 0.002; P = 0.005) were independent prognostic factors for overall survival patients with
osteosarcoma cancer.
Conclusions: In conclusion, our findings suggested that expression level of miR-26a and miR-27a contributes to
aggressive progression of this malignancy. Therefore, may have clinical potentials as a non-invasive diagnostic/prognostic
biomarker for osteosarcoma patients.
Background
Osteosarcoma is one of the most frequent primary
skeletal neoplasms, second only to plasma cell mye-
loma, in children, adolescents and young adults [1].
Despite the advances in multiple therapeutic strategies
such as chemotherapy, surgery, and sometimes radio-
therapy, overall clinical outcomes for osteosarcoma
patients is still dissatisfactory, especially for patients
with metastasis or recurrent osteosarcoma. It can be
helpful to determine novel markers for osteosarcoma,
which can accurately identify biological characteristics of
cancers, improve therapeutic strategies, and predict clinical
outcome. MicroRNAs (miRNAs) are small non-coding
RNAs 18–25 nucleotides in length which regulate gene ex-
pression through repressing translation and cleaving their
target mRNAs by binding to complementary sites in their
3′-untranslated region (3′-UTR)[2, 3]. Dys-regulation of
miRNA expression has been reported in different kinds of
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human cancers, such as breast cancer, lung cancer, and
colon cancer, chronic lymphocytic leukemia and malignant
glioma [4–7]. Different human miRNAs have been shown
to be dys-regulated in osteosarcoma [8–11].
MiR-26a was down-regulated and may serve as a poten-
tial cancer suppressor in various kinds of cancer such as
nasopharyngeal carcinoma, hepatocellular carcinoma, thy-
roid anaplastic carcinomas and breast cancer [12–14].
Moreover, miR-26a was remarkably expressed in lymph
node metastatic cancers when compared with primary
cancers and enhanced lung cancer cell migration and in-
vasion [15]. It has been reported that miR-26a can sup-
press cell differentiation, migration and invasion by
targeting a number of genes [15, 16].
MiR-27a is located at chromosome 19p13.1, belongs to
the miR-23a/24-2/27a cluster existing intergenically in
the vertebrate genome [17]. It has been reported that
aberrant expression of miR-27a occurred in different
human cancer kinds, which show it act as a regulator in
carcinogenesis. its oncogenic role has been verified in
many kinds of malignancies such as hepatocellular
carcinoma, renal cell carcinoma, breast cancer gastric
adenocarcinoma, colon cancer, and cervical cancer;
while, miR-27a is suggested to be a cancer suppressive
miRNAs in non-small cell lung cancer, oral squamous
cell carcinoma, and acute leukemia, oesophageal cancers
[18–22]. Therefore, biological role of miR-27a in cancers
is controversial. It indicated that it has context-dependent
activities.
Some studies have indicated that miR-27a expression
level is involved in promotion of proliferation, migration
and invasion in osteosarcoma cells [23].
Therefore, in current study, the clinical importance of
miR-27aand 26a in human osteosarcoma were evaluated
also their relationship with clinicopathological factors
was investigated.





expression of miR-26a expression of miR-27a P value
of miR-26a
P value
of miR-27aLow High high Low
Gender
Male 30 18 12 19 11 0.723 0.673
Female 23 15 8 10 13
Age
Children, Adolescents 20 14 6 11 9 0.634 0.694
Young adults 33 19 14 18 15
Tumor diameter (cm)
≤5 36 22 14 17 19 0.372 0.301
>5 17 11 6 12 5
Location
Distal 24 14 10 14 10 0.473 0.524
Proximal 29 19 10 15 14
Tumor grade
Low 24 13 11 11 13 0.007 0.016
High 29 20 9 11 9
Histological type
Osteoblastic 21 11 10 13 8 0.454 0.483
Chondroblastic 15 10 5 6 9
Telangiectatic 12 8 4 8 4
Fibroblastic 5 4 1 2 3
TNM stage
I + II 34 19 15 16 18 0.001 0.012
III + IV 19 14 5 13 6
Distant metastasis
Yes 16 13 3 16 0 0.004 0.001
No 37 20 17 13 24










Patients and tissue samples
We obtained 53 patients with osteosarcomas from
Mashhad Hospitals between April 2008 and September
2014. None of the patients enrolled in this study had re-
ceived and chemotherapy or radiotherapy before surgery.
Clinical data was collected from the patients’ database.
In our study, 53 pairs of osteosarcoma tissues and corre-
sponding noncancerous bone tissues were collected from
the same patients. The specimens were immediately snap-
frozen in liquid nitrogen and stored at − 80 °C until use.
Moreover, the diagnosis and the histological grading were
approved by pathologists. The clinicopathological features
were summarized in (Table 1). Ethical approval for the
study was obtained according to the Declaration of
Helsinki. All subjects were volunteers and informed con-
sents were obtained.
Quantitative real-time PCR
The expression level of miRNAsin the osteosarcoma and
corresponding non-cancer tissues was evaluated by qRT-
PCR assay. The total RNA was purified from samples
noncancerous bone tissue using TRI zolaccording to the
manufacturer’s instructions. CDNA was reverse tran-
scribed from total RNA samples using specific miR primers
from the Taq Man MicroRNA Assays and reagents from
the Taq Man MicroRNA Reverse Transcription kit (Ap-
plied Biosystems, Foster City, CA,USA. Real-time PCR was
carried out using an invitrogen kit by system of Rotor-gene
6000 (Qiagen). The universal small nuclear RNA U6
(RNU6B) was used as an endogenous control for miRNAs.
The ΔΔCt (ΔΔCt =ΔCt tumor samples – ΔCt control sample) to
qualify the relative expression level of miRNAs.
Statistical analysis
All data were presented as the mean SD and were analysed
using SPSS 16.0 software (SPSS Inc., USA). Associations
between miRNAs expression level and clinicopathological
features were determined using theχ2test. The Kaplan-
Meier method was used to estimate survival rates, and the
log-rank test was used to evaluate survival differences be-
tween groups. Cox proportional hazards multivariate sur-
vival analysis was applied to evaluate predictors correlated
with overall survival. Differences were considered statisti-
cally significant when p was less than 0.05.
Results
Our result suggested that miR-26a expression level in
osteosarcoma bone tissue was significantly lower than
that in the paired noncancerous bone tissues (mean ±
SD: 5.12 ± 2.53; 10.75 ± 3.23; P = 0.001; Fig. 1), Further-
more, miR-27a expression was higher in osteosarcoma
bone tissue in comparison with paired noncancerous bone
tissues (mean ± SD: 6.35 ± 1.23; 2.85 ± 0.64; P = 0.003;
Fig. 1). We categorized the patients into a high expression
group and a low expression group according to the me-
dian expression level of miRNAs, and the relationship of
the miR-6a and miR-7a with various clinical features was
analysed (Table 1).
The results indicated that low expression level of miR-
26a and high expression of miR-27a were associated
with high TNM stage (P = 0.001; P = 0.012), tumor grade
(P = 0.007; P = 0.016), and distant metastasis (P = 0.004;
P = 0.001). However, there were no significant correla-
tions of miR-26a and miR-27a expression levels with
other clinical features. The correlation of miR-26a and
miR27a expression with overall survival of osteosarcoma
patients was investigated by Kaplan-Meier analysis and
log-rank test. The results indicated that patients with low
expression of miR-26a and high expression of miR-27a had
shorter overall survival (log-rank test: P < 0.001; Fig. 2).
Multivariate Cox proportional hazards model analysis
showed that low expression of miR-26a and high expres-
sion of miR-27a (P = 0.021; P = 0.011), high TNM stage
(P = 0.001;P = 0.003), tumor grade (P = 0.005;P = 0.01),
and distant metastasis.(P = 0.002;P = 0.005) were inde-
pendent prognostic factors for overall survival patients
with osteosarcoma cancer (Table 2 and 3).
Discussion
Dys-regulation of miRNAs was reported to be associated
with the development and progression of human malig-
nancies [24]. Aberrant expression of circulating miRNAs
has been demonstrated to be as potential sensitive and
accurate biomarkers for cancer diagnosis and prognosis
osteosarcoma [3]. Therefore, determination of functional
and clinical importance of a specific miRNA may pro-
vide effective management of disease. In current study,
the clinical importance of miR-27a and miR-26a in hu-
man osteosarcoma were evaluated also their relationship
with clinicopathological factors was investigated.
Our result suggested that miR-26aexpression level in
osteosarcoma bone tissue was significantly lower than that
in the paired noncancerous bone tissues. The low expres-
sion level of miR-26a was associated with high TNM stage,
tumor grade, and distant metastasis. Down-regulated miR-
26a has been reported to play an important role in the pro-
gression of tumor, and miR-26a functions as a potential
tumor suppressor in different types of cancer [12–14].
Song et al. suggested that down-regulation of miR-26a is
associated with tumor aggressiveness and tumor metasta-
sis, and miR-26a inhibits cell migration and invasion by
targeting the EZH2 gene in osteosarcoma [25]. The de-
creased expression of miR-26a in osteosarcoma tissues has
been reported to be significantly correlated with adverse
clinicopathological features including adverse clinical stage
and with the presence of distant metastasis. [25].









On the other hand, miR-26a was remarkably expressed
in lymph node metastatic tumors when compared with
primary tumors and enhanced lung cancer cell migration
and invasion [15]. It has been reported that miR-26a can
suppress cell differentiation, migration and invasion by
targeting a number of genes including, SMAD1, MTDH,
CDK6, CCNE1, CCNE2 CCND2, PTEN, PB1, MAP3K2
and enhancer of zeste homolog 2 (EZH2) [15, 16]. In
current study, Kaplan-Meier analysis and log-rank test
indicated that patients with low expression of miR-26a
had shorter overall survival than those with high miR-
NAs expression.
Multivariate Cox proportional hazards model analysis
showed that low expression of miR-26a high TNM stage,
tumor grade, and distant metastasis were independent
prognostic factors for overall survival patients with
osteosarcoma cancer. It has been reported that down-
regulation of miR-26a is associated with poor prognosis
in patients with osteosarcoma, and the patients with low
miR-26a expression tended to have a shorter overall and
disease-free survival time. Also it was indicated that the
expression of miR-26a may be a prognostic factor for
overall and disease-free survival independent of these
adjusted clinicopathologic characteristics [25]. Further-
more, in the present study, miR-27a expression was
higher in osteosarcoma bone tissue in comparison with
paired noncancerous bone tissues and high expression
level of miR-27a was associated with high TNM stage,
tumor grade, and distant metastasis. Tang et al. [26]
showed that the serum levels of miR-27a expression in-
creased in osteosarcoma patients and confirmed its sig-
nificant associations with aggressive clinicopathological
features including advanced clinical stage, positive dis-
tant metastasis and poor response to chemotherapy, in-
dicating its oncogenic role in this malignancy. Aberrant
expression of miR-27a has been suggested in various hu-
man cancer kinds, which indicates it act as a regulator
in carcinogenesis. Furthermore, it has been shown that
Fig 1 MiRNAs expression levels in osteosarcoma and adjacent normal tissues
Fig 2 Relationship between miRNAs expression levels and survival time (log-rank test: P < 0.001)









miR-27a might be as oncogenic mirRNA in many kinds
of malignancies such as hepatocellular carcinoma, renal
cell carcinoma, breast cancer gastric adenocarcinoma,
colon cancer, and cervical cancer; but miR-27a is sug-
gested to be a tumor suppressive miRNAs in non-smallcell
lung cancer, oral squamous cell carcinoma, and acute
leukemia, oesophageal cancers [18–22]. Nevertheless, bio-
logical role of miR-27a in cancers is controversial. These
result suggested that it has context-dependent activities.
Moreover, miR-27a expression level can promote prolifera-
tion, migration and invasion in osteosarcoma cells [23]. A
study reported that miR-27a might have oncogenic in la-
ryngeal squamous cell carcinoma via suppressing the ex-
pression of PLK2 and serve as a diagnostic and therapeutic
biomarker in this malignancy [27]. Li et al. [28] indicated
the miR-27a was up-regulated in lung adenocarcinoma pa-
tients treated with cisplatin-based chemotherapy and con-
firmed that it might be associated with low expression of
RKIP, decreased sensitivity to cisplatin, and poor prognosis.
It has been shown that oncogenic miR-27a had important
role in ovarian cancer cell growth and metastasis [29]. Tang
et al. [26] showed that the serum levels of miR-27a expres-
sion increased in osteosarcoma patients and confirmed its
significant associations with aggressive clinicopathological
features including advanced clinical stage, positive distant
metastasis and poor response to chemotherapy, indicating
its oncogenic role in this malignancy. Nowadays, further
investigations performed on miRNAs in early detection of
cancers by the other authors [30].
In the present study, the results indicated that patients
with high expression of miR-27a had shorter overall sur-
vival than those with low miRNAs expression. Moreover,
Multivariate Cox proportional hazards model analysis
showed that high expression of miR-27a, high TNM stage,
tumor grade, and distant metastasis were independent
prognostic factors for overall survival patients with osteo-
sarcoma cancer. Tang et al. [26] found that osteosarcoma
patients with high miR-27a expression had both worse
overall and disease free survival, and demonstrated that
clinical stage, distant metastasis and serum miR-27a ex-
pression were all independent prognostic factors for both
overall and disease-free survival. They confirmed the
prognostic value of serum miR-27a expression in osteosar-
coma patients.
Conclusions
In conclusion, our findings suggested that expression level
of miR-26a and miR-27a contributes to aggressive progres-
sion of this malignancy. Therefore, may have clinical po-
tentials as a non-invasive diagnostic/prognostic biomarker
for osteosarcoma patients.
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